Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma

Valeria Sebastiani, Paolo Visca, Claudio Botti, Giuseppe Santeusanio, Gregorio Marco Galati, Valentina Piccini, Barbara Capezzone De Joannon, Ugo Di Tondo, Piero Luigi Alo

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Purpose. To explore the expression of fatty acid synthase (FAS) and human erythrocyte glucose transporter 1 (GLUT1) in endometrial carcinomas and to detect associations with clinicopathological features and prognosis. FAS and GLUT1 are two molecules involved in energy supply of normal cells. These markers are overexpressed in neoplastic tissues because of their increased necessity of energy. Methods. Ninety-five patients with endometrial carcinoma were followed-up for an average period of 5 years. FAS and GLUT1 expressions were evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tissues. Staining was determined with a semiquantitative method. Negative controls were obtained from patients submitted to hysterectomy for uterine prolapse. Results. Eighty-five cases were endometrioid, 7 were serous, and 1 was a mucinous carcinoma. Seventy-two cases (75%) were stage I, 12 (13%) were stage II, and 11 (12%) were stage III carcinomas. Sixteen (15%) carcinomas recurred. Nine patients (8%) died for cancer during the follow-up period. FAS expression was observed in 53 cases (56%). GLUT1 expression was observed in 32 (43%) cases. Statistical analysis revealed that FAS (P = 0.04) and stage (P = 0.001) of the disease were the only two independent predictors of recurrence. GLUT1 and other clinicopathologic parameters had no prognostic association. Conclusions. FAS is a reliable marker of clinically aggressive endometrial carcinomas. The knowledge of FAS expression in endometrial carcinomas is an important finding that may stratify patients into selected groups and determine therapeutic approaches for patient care.

Original languageEnglish
Pages (from-to)101-105
Number of pages5
JournalGynecologic Oncology
Volume92
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Fatty Acid Synthases
Endometrial Neoplasms
Facilitative Glucose Transport Proteins
Recurrence
Glucose Transporter Type 1
Uterine Prolapse
Carcinoma
Mucinous Adenocarcinoma
Hysterectomy
Paraffin
Formaldehyde
Patient Care
Immunohistochemistry
Staining and Labeling
Neoplasms

Keywords

  • Carcinoma
  • Endometrial
  • Fatty acid synthase
  • Prognosis

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Sebastiani, V., Visca, P., Botti, C., Santeusanio, G., Galati, G. M., Piccini, V., ... Alo, P. L. (2004). Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. Gynecologic Oncology, 92(1), 101-105. https://doi.org/10.1016/j.ygyno.2003.10.027

Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. / Sebastiani, Valeria; Visca, Paolo; Botti, Claudio; Santeusanio, Giuseppe; Galati, Gregorio Marco; Piccini, Valentina; De Joannon, Barbara Capezzone; Di Tondo, Ugo; Alo, Piero Luigi.

In: Gynecologic Oncology, Vol. 92, No. 1, 01.2004, p. 101-105.

Research output: Contribution to journalArticle

Sebastiani, V, Visca, P, Botti, C, Santeusanio, G, Galati, GM, Piccini, V, De Joannon, BC, Di Tondo, U & Alo, PL 2004, 'Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma', Gynecologic Oncology, vol. 92, no. 1, pp. 101-105. https://doi.org/10.1016/j.ygyno.2003.10.027
Sebastiani, Valeria ; Visca, Paolo ; Botti, Claudio ; Santeusanio, Giuseppe ; Galati, Gregorio Marco ; Piccini, Valentina ; De Joannon, Barbara Capezzone ; Di Tondo, Ugo ; Alo, Piero Luigi. / Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma. In: Gynecologic Oncology. 2004 ; Vol. 92, No. 1. pp. 101-105.
@article{c6c61e88e9304820be0767f6699f1eda,
title = "Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma",
abstract = "Purpose. To explore the expression of fatty acid synthase (FAS) and human erythrocyte glucose transporter 1 (GLUT1) in endometrial carcinomas and to detect associations with clinicopathological features and prognosis. FAS and GLUT1 are two molecules involved in energy supply of normal cells. These markers are overexpressed in neoplastic tissues because of their increased necessity of energy. Methods. Ninety-five patients with endometrial carcinoma were followed-up for an average period of 5 years. FAS and GLUT1 expressions were evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tissues. Staining was determined with a semiquantitative method. Negative controls were obtained from patients submitted to hysterectomy for uterine prolapse. Results. Eighty-five cases were endometrioid, 7 were serous, and 1 was a mucinous carcinoma. Seventy-two cases (75{\%}) were stage I, 12 (13{\%}) were stage II, and 11 (12{\%}) were stage III carcinomas. Sixteen (15{\%}) carcinomas recurred. Nine patients (8{\%}) died for cancer during the follow-up period. FAS expression was observed in 53 cases (56{\%}). GLUT1 expression was observed in 32 (43{\%}) cases. Statistical analysis revealed that FAS (P = 0.04) and stage (P = 0.001) of the disease were the only two independent predictors of recurrence. GLUT1 and other clinicopathologic parameters had no prognostic association. Conclusions. FAS is a reliable marker of clinically aggressive endometrial carcinomas. The knowledge of FAS expression in endometrial carcinomas is an important finding that may stratify patients into selected groups and determine therapeutic approaches for patient care.",
keywords = "Carcinoma, Endometrial, Fatty acid synthase, Prognosis",
author = "Valeria Sebastiani and Paolo Visca and Claudio Botti and Giuseppe Santeusanio and Galati, {Gregorio Marco} and Valentina Piccini and {De Joannon}, {Barbara Capezzone} and {Di Tondo}, Ugo and Alo, {Piero Luigi}",
year = "2004",
month = "1",
doi = "10.1016/j.ygyno.2003.10.027",
language = "English",
volume = "92",
pages = "101--105",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma

AU - Sebastiani, Valeria

AU - Visca, Paolo

AU - Botti, Claudio

AU - Santeusanio, Giuseppe

AU - Galati, Gregorio Marco

AU - Piccini, Valentina

AU - De Joannon, Barbara Capezzone

AU - Di Tondo, Ugo

AU - Alo, Piero Luigi

PY - 2004/1

Y1 - 2004/1

N2 - Purpose. To explore the expression of fatty acid synthase (FAS) and human erythrocyte glucose transporter 1 (GLUT1) in endometrial carcinomas and to detect associations with clinicopathological features and prognosis. FAS and GLUT1 are two molecules involved in energy supply of normal cells. These markers are overexpressed in neoplastic tissues because of their increased necessity of energy. Methods. Ninety-five patients with endometrial carcinoma were followed-up for an average period of 5 years. FAS and GLUT1 expressions were evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tissues. Staining was determined with a semiquantitative method. Negative controls were obtained from patients submitted to hysterectomy for uterine prolapse. Results. Eighty-five cases were endometrioid, 7 were serous, and 1 was a mucinous carcinoma. Seventy-two cases (75%) were stage I, 12 (13%) were stage II, and 11 (12%) were stage III carcinomas. Sixteen (15%) carcinomas recurred. Nine patients (8%) died for cancer during the follow-up period. FAS expression was observed in 53 cases (56%). GLUT1 expression was observed in 32 (43%) cases. Statistical analysis revealed that FAS (P = 0.04) and stage (P = 0.001) of the disease were the only two independent predictors of recurrence. GLUT1 and other clinicopathologic parameters had no prognostic association. Conclusions. FAS is a reliable marker of clinically aggressive endometrial carcinomas. The knowledge of FAS expression in endometrial carcinomas is an important finding that may stratify patients into selected groups and determine therapeutic approaches for patient care.

AB - Purpose. To explore the expression of fatty acid synthase (FAS) and human erythrocyte glucose transporter 1 (GLUT1) in endometrial carcinomas and to detect associations with clinicopathological features and prognosis. FAS and GLUT1 are two molecules involved in energy supply of normal cells. These markers are overexpressed in neoplastic tissues because of their increased necessity of energy. Methods. Ninety-five patients with endometrial carcinoma were followed-up for an average period of 5 years. FAS and GLUT1 expressions were evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tissues. Staining was determined with a semiquantitative method. Negative controls were obtained from patients submitted to hysterectomy for uterine prolapse. Results. Eighty-five cases were endometrioid, 7 were serous, and 1 was a mucinous carcinoma. Seventy-two cases (75%) were stage I, 12 (13%) were stage II, and 11 (12%) were stage III carcinomas. Sixteen (15%) carcinomas recurred. Nine patients (8%) died for cancer during the follow-up period. FAS expression was observed in 53 cases (56%). GLUT1 expression was observed in 32 (43%) cases. Statistical analysis revealed that FAS (P = 0.04) and stage (P = 0.001) of the disease were the only two independent predictors of recurrence. GLUT1 and other clinicopathologic parameters had no prognostic association. Conclusions. FAS is a reliable marker of clinically aggressive endometrial carcinomas. The knowledge of FAS expression in endometrial carcinomas is an important finding that may stratify patients into selected groups and determine therapeutic approaches for patient care.

KW - Carcinoma

KW - Endometrial

KW - Fatty acid synthase

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=0742324875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0742324875&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2003.10.027

DO - 10.1016/j.ygyno.2003.10.027

M3 - Article

C2 - 14751145

AN - SCOPUS:0742324875

VL - 92

SP - 101

EP - 105

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -